Associate Professor in Medicinal Chemistry
- Bernard Taylor Fellow and Tutor in Organic Chemistry
My work focuses on the discovery of new drug targets and mechanisms, and the translation of these findings into new clinical candidates.
Through several successful multidisciplinary research collaborations, my team works in a range of therapeutic areas including identifying small molecules to upregulate utrophin for the treatment of Duchenne Muscular Dystrophy (DMD), new anti-cancer agents and agents to stimulate endogenous cell populations for regenerative medicine.
I have co-founded two spin-out companies to date, MuOx Ltd (acquired by Summit plc in November 2013), for the development of new small molecule utrophin modulators for DMD therapy, and OxStem Ltd, a company to translate our research findings in small molecule manipulation of stem cells for regenerative medicine. Most recently, OxStem Ltd raised a record £16.9M to identify new classes of drugs that can re-programme or stimulate existing endogenous cells to repair tissues in age-related conditions including cancer, neurodegenerative diseases and heart failure.
As well as my active teaching commitments within the Departments of Pharmacology and Chemistry and at St John’s College, I am a member of, and contribute to, the Oxford Stem Cell Institute (OSCI), the British Heart Foundation Centre of Research Excellence (BHF CRE), and the Cancer Research UK Oxford Centre – supporting at all levels including research and training.
Structure-activity relationships and colorimetric properties of specific probes for the putative cancer biomarker human arylamine N-acetyltransferase 1.
Egleton JE. et al, (2014), Bioorg Med Chem, 22, 3030 - 3054
Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
Gianella-Borradori M. et al, (2015), Bioorg Med Chem, 23, 241 - 263
Stemistry: the control of stem cells in situ using chemistry.
Davies SG. et al, (2015), J Med Chem, 58, 2863 - 2894
A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.
Kerr AG. et al, (2017), J Pharmacol Exp Ther, 361, 417 - 428
Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
Bataille CJ. et al, (2017), Bioorg Med Chem, 25, 2657 - 2665
Dihydrobenz[e][1,4]oxazepin-2(3H)-ones, a new anthelmintic chemotype immobilising whipworm and reducing infectivity in vivo.
Partridge FA. et al, (2017), PLoS Negl Trop Dis, 11
Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth.
McIntyre A. et al, (2016), Cancer Res, 76, 3744 - 3755
Chemical-Induced Naive Pluripotency.
Russell AJ. and Silpa L., (2016), Cell Chem Biol, 23, 532 - 534